Tzu-Fei Wang: Drug–Drug Interactions Between DOACs and Prostate Cancer Therapies
Tzu-Fei Wang, Associate Professor at University of Ottawa, The Ottawa Hospital, and The Ottawa Hospital Research Institute, shared on LinkedIn about a recent article she and her colleagues co-authored, published in Cancer, adding:
“Concerned about drug – drug interactions between DOACs and prostate cancer therapies?
New study of 2,297 patients from Ontario and Alberta:
No increase in thrombosis with DOACs and enzalutamide or apalutamide
No increase in bleeding with DOAC and abiraterone
Reassuring real-world data for clinicians to guide anticoagulation!”
Title: Risks of thrombosis and hemorrhage in concurrent use of anticoagulants and potential interacting prostate cancer agents
Authors: Tzu-Fei Wang, Anna Clarke, Mitchell Rath, Samantha Yoo, Deena Fremont , Cynthia Wu , Pietro Ravani , Dominick Bossé , Robert Talarico, Marc Carrier , Manish M. Sood
Stay updated on all scientific advances with Hemostasis Today.
-
May 6, 2026, 18:03Shiv Choudhary: Did You Know That Varicose Veins Can Be Detected with a Simple Test?
-
May 6, 2026, 17:48A Hidden Mechanical Cause of Recurrent Thrombosis in a Young Athlete – The Lancet
-
May 6, 2026, 17:26Joanna Fraser: Highlights from WFH Congress 2026 in Malaysia
-
May 6, 2026, 17:04Nour Al-Mozain: Massive Transfusion in Pediatrics
-
May 6, 2026, 16:36Ney Carter Borges: Randomized Trial of the Vascular Effects of Low-Dose Colchicine in High-Risk Type 2 Diabetes
-
May 6, 2026, 16:35Giuseppe Lippi: Essential Laboratory Testing in Emergencies
-
May 6, 2026, 16:28Anna-Maria Tsilia: Addressing Psychological Aspects of Hemophilia at WFH 2026
-
May 6, 2026, 16:25Manuel A. Lopez Serrano: Mastering Healthcare Through Family, Faith, and Hemophilia
-
May 6, 2026, 16:24Elena Donoso Úbeda: Attending WFH 2026 for Manual Therapy Workshop and Global Collaboration